Reviewing patients using opioid medicines long-term for non-cancer pain

Similar documents
Appropriate prescribing of Oxycodone for non-cancer pain in general practice

Reviewing the long-term use of selective serotonin reuptake inhibitors in patients with depression

Improving safety for patients taking an ACE inhibitor/arb + diuretic

Lowering serum urate levels in patients with gout

Identifying patients who may benefit from stepping down PPI treatment

Optimising asthma management in high risk patients

Monitoring polypharmacy and reducing problematic prescribing

CLINICAL AUDIT. Safe and Effective. Anticoagulation. with Warfarin

CLINICAL AUDIT. The safe and effective use of. Methotrexate

CLINICAL AUDIT. Renal Function Testing in People. Taking Dabigatran

CLINICAL AUDIT. Laboratory Investigation of. UTI in Primary Care

CLINICAL AUDIT. Laboratory Testing in. Diabetes. in Primary Care

CLINICAL AUDIT. Initiating Insulin. in Patients with Type 2 Diabetes

Asthma: Bronchodilator Overuse Review (MOPS Accredited until August 2020)

Safe use of Lithium therapy

Sore throat management of at-risk people

Monitoring of Thyroid Replacement Therapy

The Laboratory Investigation of. Tiredness. Clinical Audit. better medicin

Application for Endorsement of CQI (Clinical Audit) Activities for MOPS Credits Allocation

Application for Endorsement of CQI (Clinical Audit) Activities for MOPS Credits Allocation

CLINICAL POLICY Clinical Policy: Extended Release Opioid Analgesics

Clinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.18

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.19

Clinical Policy: Opioid Analgesics Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid

Dr Alistair Dunn. General Practitioner Northland District Health Board Whangarei

The fear of enabling. How to distinguish MISUSE OF PRESCRIPTION OPIOIDS: Steve s story a true account of prescription medicine misuse

RECERTIFICATION PROGRAMME FOR CONTINUING PROFESSIONAL DEVELOPMENT OF OPTOMETRISTS

PALLIATIVE CARE PRESCRIBING FOR PATIENTS WHO ARE SUBSTANCE MISUSERS

Update on OXYCODONE. what can primary care do about the problem? 8 BPJ Issue 44

CDC Guideline for Prescribing Opioids for Chronic Pain

RECERTIFICATION PROGRAMME FOR CONTINUING PROFESSIONAL DEVELOPMENT OF OPTOMETRISTS

Methadone/Buprenorphine 101

Opioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018

Oxycodone. Dr Alistair Dunn Addiction Medicine Specialist & General Practitioner

Guidance on competencies for Paediatric Pain Medicine reviewed 2017

Primary care review of Tramadol Prescribing

National Guidelines. Interim methadone prescribing

Virginia. Prescribing and Dispensing Profile. Research current through November 2015.

California. Prescribing and Dispensing Profile. Research current through November 2015.

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority

GUIDELINES AND AUDIT IMPLEMENTATION NETWORK

Berkshire West Area Prescribing Committee Guidance

Guidance for CPD Providers. Information and help for organisations providing CPD for chiropractors

Guidelines for the Management of Chronic Non-Malignant Pain (CNMP) in Primary Care (not including neuropathic pain (NeP).

Mr John Moffat. Mr Chris Gregg. Dr Chris Hoffman. Dr Wei Chung Tong

Rule Governing the Prescribing of Opioids for Pain

Switching Tramacet to paracetamol alone or paracetamol and codeine

Opioid Management Change Package 2017/2018

SCOPING DOCUMENT FOR WHO Treatment Guidelines on pain related to cancer, HIV and other progressive life-threatening illnesses in adults

DURATION LIMIT CRITERIA ACETAMINOPHEN/ASPIRIN/IBUPROFEN CONTAINING OPIOID ANALGESICS (BRAND AND GENERIC) (acetaminophen and benzhydrocodone)

October National Health Committee. Epidermal Growth Factor Receptor Mutation Testing: Supplement to Recommendation Update

DURATION LIMIT WITH QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA IMMEDIATE-RELEASE OPIOID ANALGESICS (BRAND AND GENERIC)*

Drug Name (specify drug) Quantity Frequency Strength

bpac better e m dicine

Breast screening. achieving equity. Key concepts: keyword: breastscreening

MINNESOTA PMP UTILIZATION IN THE EMERGENCY DEPARTMENT

Drug Name (specify drug) Quantity Frequency Strength

Non-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients

Navigating Pain Management during the Opioid Epidemic: Focus Group Findings

Proposed Changes to Existing Measure for HEDIS : Use of Opioids at High Dosage (UOD)

Diabetes Subcommittee of PTAC meeting held 3 March (minutes for web publishing)

Ms Anne Dowden. Independent Evaluation Consultant Wellington

Application form for an Annual Practising Certificate 2017/2018 Application form for updating Practising Status 2017/2018 (Annual Renewal)

Prescribing drugs of dependence in general practice, Part C

Medicare Part D Opioid Policies for 2019 Information for Patients

10/08/59 PAIN IS THE MOST COMMON TREATABLE SYMPTOM OF CANCER CURRENT EVIDENCE BASED CONCEPTS: MANAGEMENT OF CANCER PAIN PAIN AN UNMET CLINICAL NEED IN

New Guidelines for Prescribing Opioids for Chronic Pain

Dr Alistair Dunn. Lead Clinician Northland Health Community Mental Health & Addictions Northland DHB Whangarei

NRT Voucher redemption scheme service specification

Immediate Release Opioid Analgesics (Brand and Generic): Acute Pain Duration Limit with MME Limit and Post Limit Policy

OPIOIDS AND NON-CANCER PAIN

Management of Pain - A Comparison of Current Guidelines

Safe Prescribing of Drugs with Potential for Misuse/Diversion

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Opioid Prescribing for Acute Pain. Care for People 15 Years of Age and Older

See Important Reminder at the end of this policy for important regulatory and legal information.

Oregon Opioid Overdose Prevention Initiative

Competencies for Cervical Screening Education and Training

New regulatory requirements DPCS Regulations 2017

Q&A: Opioid Prescribing for Chronic Non-Malignant Pain

Acetaminophen/Aspirin/Ibuprofen Containing Immediate Release Opioid Analgesics: Quantity Limit Policy

Medicines Optimisation Strategy

bpac nz better medicine Palliative Care Quiz Feedback

Chronic Non Malignant Pain Opioid Guideline

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION

QUALITY IMPROVEMENT TOOLS

Professional Development: proposals for assuring the continuing fitness to practise of osteopaths. draft Peer Discussion Review Guidelines

Application form for an Annual Practising Certificate 2018/2019 Application form for updating Practising Status 2018/2019 (Annual Renewal)

Oklahoma. Prescribing and Dispensing Profile. Research current through November 2015.

Submission - The Substance Addiction Compulsory Assessment and Treatment (SACAT) Bill

Controlled Substances: A survey of tools and resources required by hospital pharmacists

SHARED CARE GUIDELINE For

Neuropathic pain MID ESSEX LOCALITY

Proposal on subsidy changes for some respiratory inhalation products and access restrictions to combination inhalers.

FITNESS INDUSTRY EDUCATION Analyse ethical principles and practice in the fitness industry

Transcription:

CLINICAL AUDIT Reviewing patients using opioid medicines long-term for non-cancer pain Valid to March 2023 bpac nz better medicin e

Audit focus This audit helps primary care health professionals optimise the management of patients prescribed opioid medicines in their practice. The aim is to ensure that patients who have been using these medicines long-term for the treatment of non-cancer pain have their medicine regimen regularly reviewed, in order to determine if ongoing use is appropriate; withdrawal can be discussed with patients for whom ongoing use is not indicated. Patients using these medicines for the management of pain associated with cancer or other palliative care conditions are not covered by this audit. Clinicians could also use the audit to assess other medicines used long-term for the management of chronic pain, such as gabapentin. Background Strong opioid medicines are recommended at Step Three of the World Health Organisation pain ladder, and are typically reserved for the treatment of severe acute pain or moderate to severe chronic pain, depending on a patient s response to other analgesics. There are few situations when a strong opioid would be initiated for acute pain in primary care. More common scenarios for General Practitioners are renewing a prescription of a strong opioid medicine for patients discharged from hospital, renewing prescriptions of strong opioids for patients with chronic pain managed in primary care or initiating or renewing prescriptions of weaker opioids such as tramadol or codeine. Opioid medicines are potentially addictive. Dispensing data from New Zealand show that for each year, over the last five years, approximately one-fifth of the population received an opioid medicine. 1 The focus of discussion regarding addiction to opioid medicines is often on strong opioids such as oxycodone, however, the same prescribing cautions should be applied to weaker opioids, such as tramadol, to minimise the risk of inappropriate use. Dispensing data from New Zealand show that tramadol use increased by 13% from 2013 to 2015. Patients using opioid medicines should be encouraged to adopt and continue with non-pharmacological approaches to managing pain, such as exercise, physiotherapy and relaxation. Clinicians can consider the use of multimodal analgesia, such as using paracetamol in combination with an opioid medicine, in order to reduce the dose of opioid medicines required and therefore reduce a patient s risk of adverse effects, as well as provide analgesia when the opioid medicine is withdrawn. Clinical guidelines recommend that patients should be reviewed within one to four weeks of initiating an opioid medicine or increasing dose, as patients can become dependent as early as one month after initiating opioid medicines. 2, 3 For patients using these medicines long-term, review on a three-monthly basis is recommended, or more often if required. 3 Reviewing patients using opioid medicines long-term can ensure that the medicines and doses they are prescribed are still appropriate for their underlying condition and degree of pain they experience, as well as allowing the opportunity to assess for the development of potential adverse effects. Withdrawing patients who have become dependent on opioid medicines can be a difficult process, particularly if this is being managed in primary care without the patient having access to additional support from addiction services or a pain clinic in secondary care. The focus of this audit is on identifying patients who are using opioids long-term and ensuring they are reviewed. Withdrawing patients from opioid medicines is not included in the audit process. For further information on withdrawing patients who are dependent on opioid medicines, see: www.bpac.org.nz/ BPJ/2014/October/opioid-addiction.aspx Plan Summary This audit identifies patients who have been prescribed an opioid medicine for three months or more in order to assess whether the choice of medicine(s) and doses remain appropriate. 4 Recommended audit standards Ideally, all patients who have been taking an opioid medicine for the management of non-cancer pain for three months or 1. Pharmaceutical Claims Collection, Ministry of Health, 2018. 2. Manchikanti L, Kaye AM, Knezevic NN, et al. Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians (ASIPP) guidelines. Pain Physician 2017;20:S3 92 3. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain - United States, 2016. JAMA 2016;315:1624 45. doi:10.1001/jama.2016.1464 4. If this audit is used to identify patients taking other analgesic medicines long-term, such as gabapentin, clinicians can choose a timeframe appropriate for the medicine in question 2 Reviewing patients using opioid medicines long-term for non-cancer pain Clinical Audit www.bpac.org.nz/audits

more should have a documented discussion in their notes about the intended duration of opioid medicine use and a plan for withdrawal. This could also include whether the addition of another analgesic medicine is appropriate in order to reduce the dose of opioid medicine(s) required or whether switching to another analgesic medicine is appropriate. If there is no documented evidence of a discussion, the patient should be flagged for review. Data Identifying eligible patients You will need to have a system in place that allows you to identify patients using opioid medicines for a period of three months or more. Many practices will be able to do this by running a query through their PMS. The notes of identified patients will need to be reviewed in order to ascertain the clinical indication for the prescription of opioids; patients using opioid medicines for the management of pain associated with cancer or another palliative care condition can be excluded from the audit. Sample size A sample size of 30 patients is sufficient for the purpose of the audit. However, it is recommended that all eligible patients using opioid medicines long-term for the management of non-cancer pain are subsequently reviewed. Criteria for a positive result A positive result is if a patient who has been prescribed an opioid medicine for three months or more has a documented discussion in their notes regarding their pain management plan. This discussion could include the expected duration of use of opioid medicines, the use of other analgesics which could be used in combination with opioids to help patients manage their pain, non-pharmacological strategies for pain management and whether withdrawing from an opioid medicine is appropriate or has been attempted. During the review, clinicians can consider factors such as: Has the patient s underlying condition changed, e.g. is a greater or lesser extent of pain relief required? Are the prescribed opioid medicine(s) still the most appropriate choice? Should doses be adjusted or other non-opioid analgesics initiated? Should the patient be referred for additional support for non-pharmacological pain management, e.g. to a physiotherapist? Does the patient require assistance from addiction services? Identifying opportunities for Audit of Medical Practice The first step to improving medical practice is to identify the criteria where gaps exist between expected and actual performance and then to decide how to change practice. Once a set of priorities for change have been decided on, an action plan should be developed to implement any changes. Taking action It may be useful to consider the following points when developing a plan for action (RNZCGP 2002). Problem solving process What is the problem or underlying problem(s)? Change it to an aim What are the solutions or options? What are the barriers? How can you overcome them? Overcoming barriers to promote change Identifying barriers can provide a basis for change What is achievable find out what the external pressures on the practice are and discuss ways of dealing with them in the practice setting Identify the barriers Develop a priority list Choose one or two achievable goals Effective interventions No single strategy or intervention is more effective than another, and sometimes a variety of methods are needed to bring about lasting change Interventions should be directed at existing barriers or problems, knowledge, skills and attitudes, as well as performance and behaviour Clinical Audit Reviewing patients using opioid medicines long-term for non-cancer pain 3

Review Monitoring change and progress It is important to review the action plan develop previously against the timeline at regular intervals. It may be helpful to review the following questions: Is the process working? Are the goals for improvement being achieved? Are the goals still appropriate? Do you need to develop new tools to achieve the goals you have set? Following the completion of the first cycle, it is recommended that the doctor completes the first part of the Audit of Medical Practice summary sheet (Appendix 1). Undertaking a second cycle In addition to regular reviews of progress with the practice team, a second audit cycle should be completed in order to quantify progress on closing the gaps in performance. It is recommended that the second cycle be completed within 12 months of completing the first cycle. The second cycle should begin at the data collection stage. Following the completion of the second cycle it is recommended that practices complete the remainder of the Audit of Medical Practice summary sheet. Claiming MOPS credits This audit has been endorsed by the RNZCGP as an Audit of Medical Practice activity (previously known as Continuous Quality Improvement CQI) for allocation of MOPS credits; 10 credits for a first cycle and 10 credits for a second cycle. General practitioners taking part in this audit can claim credits in accordance with the current MOPS programme. To claim points go to the RNZCGP website: www. rnzcgp.org.nz Record your completion of the audit on the MOPS Online credit summary, under the Audit of Medical Practice section. From the drop down menu, select the audit from the list or select Approved practice/ PHO audit and record the audit name in Notes, the audit date and 10 credits. General practitioners are encouraged to discuss the outcomes of the audit with their peer group or practice. As the RNZCGP frequently audit claims you should retain the following documentation, in order to provide adequate evidence of participation in this audit: 1. A summary of the data collected 2. An Audit of Medical Practice (CQI) Activity summary sheet (included as Appendix 1). Te Whare Tohu Rata o Aotearoa Endorsed CPD Activity bpac nz 10 George Street PO Box 6032, Dunedin phone 03 477 5418 free fax 0800 bpac nz bpac nz better medicin e www.bpac.org.nz/audits

Data sheet cycle 1 Reviewing patients using opioid medicines long-term for non-cancer pain Patient prescribed an opioid medicine for the management of non-cancer pain relief for three months or more Patient Patient has a documented pain management plan discussion in their notes * YES/NO 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Data Summary / 30 Percent of patients with pain management plan discussion in their notes % * Patients without a documented discussion in their notes should be flagged for review Please retain this sheet for your records to provide evidence of participation in this audit.

Data sheet cycle 2 Reviewing patients using opioid medicines long-term for non-cancer pain Patient prescribed an opioid medicine for the management of non-cancer pain relief for three months or more Patient Patient has a documented pain management plan discussion in their notes * YES/NO 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Data Summary / 30 Percent of patients with pain management plan discussion in their notes % * Patients without a documented discussion in their notes should be flagged for review Please retain this sheet for your records to provide evidence of participation in this audit.

APPENDIX 1 SUMMARY SHEET Audit of medical practice (CQI activity) Topic: Date: Reviewing patients using opioid medicines long-term for non-cancer pain Activity designed by (name of organisation, if relevant): Bpac nz Doctor s name: Results discussed with peer group or colleagues? Date: Yes No FIRST CYCLE DATA: Date of data collection: CHECK: Describe any areas targeted for improvement as a result of analysing the data collected. (If the findings have any implications for health equity, please include this.) ACTION: Describe how these improvements will be implemented. MONITOR: Describe how well the process is working. When will you undertake a second cycle? AUGUST 2016 1

SECOND CYCLE DATA: Date of data collection: CHECK: Describe any areas targeted for improvement as a result of analysing the data collected. (If the findings have any implications for health equity, please include this.) ACTION: Describe how these improvements will be implemented. MONITOR: Describe how well the process is working. COMMENTS: AUGUST 2016 PO Box 10440, The Terrace, Wellington 6134, New Zealand T +64 4 496 5999 F +64 4 496 5997 E rnzcgp@rnzcgp.org.nz W www.rnzcgp.org.nz